Cancel anytime
Omega Therapeutics Inc (OMGA)OMGA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/02/2024: OMGA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -50.25% | Upturn Advisory Performance 2 | Avg. Invested days: 34 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -50.25% | Avg. Invested days: 34 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/02/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.89M USD |
Price to earnings Ratio - | 1Y Target Price 9.5 |
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Volume (30-day avg) 400135 | Beta 1.84 |
52 Weeks Range 0.75 - 6.30 | Updated Date 12/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 48.89M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Dividends yield (FY) - | Basic EPS (TTM) -1.32 | Volume (30-day avg) 400135 | Beta 1.84 |
52 Weeks Range 0.75 - 6.30 | Updated Date 12/2/2024 |
Earnings Date
Report Date 2024-11-15 | When - |
Estimate -0.2717 | Actual -0.3 |
Report Date 2024-11-15 | When - | Estimate -0.2717 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -776.95% |
Management Effectiveness
Return on Assets (TTM) -25.37% | Return on Equity (TTM) -129.15% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 146644366 | Price to Sales(TTM) 7.74 |
Enterprise Value to Revenue 18.12 | Enterprise Value to EBITDA -2.12 |
Shares Outstanding 55366200 | Shares Floating 21329536 |
Percent Insiders 1.62 | Percent Institutions 90.43 |
Trailing PE - | Forward PE - | Enterprise Value 146644366 | Price to Sales(TTM) 7.74 |
Enterprise Value to Revenue 18.12 | Enterprise Value to EBITDA -2.12 | Shares Outstanding 55366200 | Shares Floating 21329536 |
Percent Insiders 1.62 | Percent Institutions 90.43 |
Analyst Ratings
Rating 4.43 | Target Price 13 | Buy 2 |
Strong Buy 4 | Hold 1 | Sell - |
Strong Sell - |
Rating 4.43 | Target Price 13 | Buy 2 | Strong Buy 4 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
Omega Therapeutics Inc: A Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 2017 by industry veterans in gene editing and mRNA technology.
- Initial focus on gene editing tools for research and therapeutic development.
- Recent pivot to mRNA therapeutics for rare liver diseases, leveraging expertise in lipid nanoparticle delivery systems.
Core business areas:
- Therapeutics: Development of mRNA therapeutics for alpha-1 antitrypsin deficiency (AATD) and other rare metabolic disorders.
- Research Tools: Providing engineered Cas9 enzymes and other gene editing tools to research institutions and pharmaceutical companies.
Leadership team and corporate structure:
- Led by CEO and co-founder Dr. Geoffrey Kempler, a veteran in gene therapy and drug development.
- Strong leadership team with extensive experience in mRNA, drug development, and commercialization.
- Publicly traded company headquartered in Cambridge, Massachusetts, with research facilities in both the US and Europe.
Top Products and Market Share:
Top products:
- OME-501: mRNA therapeutic for AATD, currently in Phase 2 clinical trial.
- Proprietary SpCas9: Engineered Cas9 protein used in gene editing research.
Market Share:
- AATD is a rare disease with limited treatment options. OME-501 represents a potential first-in-class mRNA therapy addressing the core cause of the disease.
- Early-stage development with no direct competitors yet.
- Potential for significant market share if OME-501 demonstrates efficacy and safety in later-stage trials.
Total Addressable Market:
- AATD: Estimated 140,000 individuals globally, representing a multi-billion-dollar market opportunity.
- Gene editing research tools: Growing market estimated to reach $5.9 billion by 2027.
Financial Performance:
- Early-stage company, primarily focused on R&D.
- No commercialized products yet, resulting in minimal revenue.
- Recent funding rounds and partnerships provide capital for ongoing clinical trials and development activities.
- Cash flow primarily focused on operational expenses and R&D investment.
- Stock price fluctuates significantly due to its pre-revenue stage and dependence on clinical trial outcomes.
Dividends and Shareholder Returns:
- No dividend payments as the company focuses on reinvesting capital for growth.
- Shareholder returns heavily dependent on future clinical trial results and potential commercialization.
Growth Trajectory:
- High growth potential driven by promising mRNA platform for rare disease treatment.
- OME-501 Phase 2 results expected in 2024, potentially driving significant market share and revenue growth.
- Expansion into additional rare metabolic disorders and gene editing technology partnerships will further drive future growth.
Market Dynamics:
- Growing mRNA therapeutics market fueled by advancements and success stories in other disease areas.
- Increasing focus on rare disease development due to unmet needs and high orphan drug pricing potential.
- Intense competition in the gene editing space with multiple players focusing on various gene editing applications.
Potential Challenges and Opportunities:
Challenges:
- Competition in the AATD and broader rare disease market.
- Success of OME-501 and future pipeline candidates dependent on clinical trial outcomes.
- Maintaining funding for ongoing development and potential commercialization.
Opportunities:
- First-in-class potential for OME-501 in AATD, offering significant clinical and commercial advantage.
- Expansion into additional rare metabolic disorders with potentially high unmet needs.
- Partnering with established pharmaceutical companies to accelerate clinical development and market access.
Recent Acquisitions:
- Acquisition of Promaxo Ltd in 2021, acquiring lipid nanoparticle delivery platform expertise for improved mRNA therapeutics.
- Integration of Promaxo technology expands potential for future development projects beyond AATD.
AI-Based Fundamental Rating:
7/10
- Strong potential driven by promising pipeline and growing mRNA space.
- Early stage with uncertainties in clinical development timeline and market success.
- High-risk, high-reward investment opportunity suitable for long-term investors.
Sources:
- Omega Therapeutics Inc website: https://omegatherapeutics.com/
- SEC filings: https://www.sec.gov/edgar/search/#/company?cikv=1836149
- Market research reports: https://www.globenewswire.com/, https://www.statista.com/
Disclaimers:
- This analysis is for informational purposes only and does not constitute financial advice.
- Investment decisions should be based on individual financial circumstances, risk tolerance, and consultation with a professional financial advisor.
##Conclusion:
- Omega Therapeutics Inc presents an exciting growth opportunity in the mRNA therapeutics space.
- With a promising pipeline and growing rare disease market, the company holds potential for significant investor returns. However, investors must be prepared for the inherent risks associated with early-stage biotechnology companies.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omega Therapeutics Inc
Exchange | NASDAQ | Headquaters | Cambridge, MA, United States |
IPO Launch date | 2021-07-30 | President, CEO & Board Director | Mr. Mahesh Karande |
Sector | Healthcare | Website | https://omegatherapeutics.com |
Industry | Biotechnology | Full time employees | 93 |
Headquaters | Cambridge, MA, United States | ||
President, CEO & Board Director | Mr. Mahesh Karande | ||
Website | https://omegatherapeutics.com | ||
Website | https://omegatherapeutics.com | ||
Full time employees | 93 |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.